Cargando…

Population Pharmacokinetics of Posaconazole in Immune-Compromised Children and Assessment of Target Attainment in Invasive Fungal Disease

BACKGROUND AND OBJECTIVE: Posaconazole (PSZ) is a triazole antifungal for the management of invasive fungal disease (IFD) in adults and children. Although PSZ is available as an intravenous (IV) solution, oral suspension (OS) and delayed-release tablets (DRTs), OS is the preferred formulation for pe...

Descripción completa

Detalles Bibliográficos
Autores principales:	McCann, Sean, Sinha, Jaydeep, Wilson, William S., McKinzie, Cameron J., Garner, Lauren M., Gonzalez, Daniel
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2023
Materias:	Original Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10338595/ https://www.ncbi.nlm.nih.gov/pubmed/37179512 http://dx.doi.org/10.1007/s40262-023-01254-2

Ejemplares similares

Evaluation of Posaconazole Pharmacokinetics in Adult Patients with Invasive Fungal Infection
por: Allegra, Sarah, et al.
Publicado: (2017)

Pharmacokinetics and safety of posaconazole delayed-release tablets for invasive fungal infections
por: Wiederhold, Nathan P
Publicado: (2015)

Posaconazole in the management of refractory invasive fungal infections
por: Langner, Stefan, et al.
Publicado: (2008)

Pharmacokinetics and Pharmacodynamics of Posaconazole
por: Chen, Lu, et al.
Publicado: (2020)

In their own words: disaster and emotion, suffering, and mental health
por: McKinzie, Ashleigh Elain
Publicado: (2018)

Phase 3 pharmacokinetics and safety study of a posaconazole tablet formulation in patients at risk for invasive fungal disease
por: Cornely, Oliver A., et al.
Publicado: (2016)

Cost-effectiveness of implementing routine hearing screening using a tablet audiometer for pediatric cystic fibrosis patients receiving high-dose IV aminoglycosides
por: Huang, Shirley P, et al.
Publicado: (2021)

Prevention of invasive fungal infections in immunocompromised patients: the role of delayed-release posaconazole
por: Soysal, Ahmet
Publicado: (2015)

Pharmacokinetics of Intravenous Posaconazole in Critically Ill Patients
por: Sime, Fekade B., et al.
Publicado: (2018)

A Review of Population Pharmacokinetic Models of Posaconazole
por: Ding, Qin, et al.
Publicado: (2022)

Phase 1b/3 Pharmacokinetics and Safety Study of Intravenous Posaconazole in Adult Asian Participants at High Risk for Invasive Fungal Infections
por: Wu, Depei, et al.
Publicado: (2022)

1469 Posaconazole salvage treatment for invasive fungal infection : a single center experience with utilization of posaconazole oral suspension or delayed-released tablet
por: Kim, Jong Hun, et al.
Publicado: (2014)

Development, clinical utility, and place in therapy of posaconazole for prevention and treatment of invasive fungal infections
por: Zoller, Emily, et al.
Publicado: (2010)

Clinical Pharmacokinetics and Dose Recommendations for Posaconazole in Infants and Children
por: Boonsathorn, Sophida, et al.
Publicado: (2018)

External evaluation of published population pharmacokinetic models of posaconazole
por: Huang, Shuqi, et al.
Publicado: (2022)

1161. Effectiveness of Posaconazole in the Treatment of Rare Invasive Fungal Infections: A Systematic Literature Review
por: Bernauer, Mark, et al.
Publicado: (2020)

755. Posaconazole versus voriconazole as antifungal prophylaxis for invasive fungal diseases in patients with hematological malignancies
por: Almutairy, Reem F, et al.
Publicado: (2020)

Clinical Outcomes of the Oral Suspension vs Delayed-Release Tablet Formulations of Posaconazole for Prophylaxis of Invasive Fungal Infections
por: Tallman, Gregory B, et al.
Publicado: (2017)

Clinical Outcomes of Oral Suspension versus Delayed-Release Tablet Formulations of Posaconazole for Prophylaxis of Invasive Fungal Infections
por: Furuno, Jon P., et al.
Publicado: (2018)

Posaconazole Pharmacokinetics in Healthy Cats after Oral and Intravenous Administration
por: Mawby, D.I., et al.
Publicado: (2016)

Correction to: Clinical Pharmacokinetics and Dose Recommendations for Posaconazole in Infants and Children
por: Boonsathorn, Sophida, et al.
Publicado: (2018)

Comparative evaluation of isavuconazonium sulfate, voriconazole, and posaconazole for the management of invasive fungal infections in an academic medical center
por: Van Matre, Edward T., et al.
Publicado: (2019)

Intravenous-oral itraconazole versus oral posaconazole in preventing invasive fungal diseases for acute leukemia patients
por: Liu, Li, et al.
Publicado: (2023)

Pharmacokinetic/pharmacodynamic study of posaconazole delayed-release tablet in a patient with coexisting invasive aspergillosis and mucormycosis
por: Leelawattanachai, Pannee, et al.
Publicado: (2019)

Pharmacokinetic and Exposure Response Analysis of the Double-Blind Randomized Study of Posaconazole and Voriconazole for Treatment of Invasive Aspergillosis
por: Maertens, Johan A., et al.
Publicado: (2023)

Evaluation of family planning and abortion education in preclinical curriculum at a large midwestern medical school
por: Brown, Lucy, et al.
Publicado: (2022)

Effectiveness of Posaconazole in Recalcitrant Fungal Keratitis Resistant to Conventional Antifungal Drugs
por: Altun, A., et al.
Publicado: (2014)

Hyperlipidemia Alters the Pharmacokinetics of Posaconazole and Vincristine Upon Co-Administration in Rats
por: Khalil, Hadeel A., et al.
Publicado: (2017)

Pharmacokinetics of Venetoclax Co-Administered with Posaconazole in Patients with Acute Myeloid Leukemia
por: De Gregori, Simona, et al.
Publicado: (2023)

Role of New Antifungal Agents in the Treatment of Invasive Fungal Infections in Transplant Recipients: Isavuconazole and New Posaconazole Formulations
por: Li, Julius, et al.
Publicado: (2015)

Prevention of Invasive Aspergillus Fungal Infections with the Suspension and Delayed-Release Tablet Formulations of Posaconazole in Patients with Haematologic Malignancies
por: Leclerc, Elisabeth, et al.
Publicado: (2018)

Making the Transition from Student to Resident: A Method to Individualize a PGY1 Program
por: Thompson, Amy N., et al.
Publicado: (2016)

Posaconazole for lobomycosis
por: Pasqualotto, Alessandro C., et al.
Publicado: (2021)

Primary or Secondary Prophylaxis with Voriconazole Compared with Posaconazole for Prevention of Invasive Fungal Infections After Hematopoietic Stem Cell Transplantation
por: Jansen, Jeffrey W, et al.
Publicado: (2017)

Cost-Effectiveness of Posaconazole Tablets for Invasive Fungal Infections Prevention in Acute Myelogenous Leukemia or Myelodysplastic Syndrome Patients in Spain
por: Cámara, Rafael, et al.
Publicado: (2017)

2736. Real-world Effectiveness of Posaconazole Prophylaxis in Preventing Invasive Fungal Infections in Recipients of Allogeneic Stem Cell Transplantation
por: Álvarez-Ortega, Carolina, et al.
Publicado: (2023)

A kinetic fluorescence assay reveals unusual features of Ca(++) uptake in Plasmodium falciparum-infected erythrocytes
por: Zipprer, Elizabeth M, et al.
Publicado: (2014)

Clinical pharmacokinetics and dose recommendations for posaconazole gastroresistant tablets in children with cystic fibrosis
por: Bentley, Siân, et al.
Publicado: (2021)

The Effect of Posaconazole and Isavuconazole on the Pharmacokinetics of Erdafitinib in Beagle Dogs by UPLC-MS/MS
por: Ruan, Lan-hong, et al.
Publicado: (2021)

Dosing Optimization of Posaconazole in Lung-Transplant Recipients Based on Population Pharmacokinetic Model
por: Dvořáčková, Eliška, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_uhb16vcusamh8bi4ffmgp1igpv